Lange B.J.,Children's Hospital of Philadelphia |
Yang R.K.,University of Wisconsin - Madison |
Gan J.,University of Wisconsin - Madison |
Hank J.A.,University of Wisconsin - Madison |
And 5 more authors.
Pediatric Blood and Cancer | Year: 2011
Purpose: To assess associations of soluble IL-2 receptor alpha (sIL-2rα) concentration with outcomes in pediatric acute myeloid leukemia (AML) in a phase 3 trial of IL-2 therapy. Procedures: We randomized 289 children with AML in first remission after intensive chemotherapy to receive IL-2 infused on days 0-3 and 8-17 (IL-2 group) or no further therapy (AML control group). We measured sequential serum sIL-2rα concentrations in both groups before, during and after therapy in both groups and in reference controls without AML. Results: Before treatment, mean sIL-2rα concentrations were similar in the IL-2 group and AML controls, but significantly higher than in reference controls. Both AML groups experienced reduction in sIL-2rα concentration after chemotherapy. Thereafter in the IL-2 group, mean sIL-2rα concentration increased from 2,669pg/ml before IL-2 to 15,534pg/ml on day 4 (P<0.001) and 10,585pg/ml on day 18 (P<0.001). In the control group sIL-2rα concentration did not change after 28 days of follow-up. Five-year disease-free survival (DFS) was 51% in the IL-2 group and 58% in the controls (P=0.489) and overall survival was 70% and 73%, respectively (P=0.727). Conclusion: SIL-2rα concentration was elevated in AML at diagnosis and tended to normalize after chemotherapy. IL-2 infusion significantly increased sIL-2rα concentration, but did not improve DFS or survival in pediatric AML. Furthermore, sIL-2rα concentration was not predictive of outcome before, during or after treatment for AML. © 2011 Wiley-Liss, Inc.